AB1063 The use of glucocorticosteroids does not dismiss the lumbar bone mineral density in patients with rheumatoid arthritis, prospective study

Background The increase of pro-inflammatory cytoquines plays a relevant role in the loss of bone density which is associated to the Rheumatoid Arthritis (RA). The glucocorticosteroids (GC) are in the base of the treatment and have been described as a losing body mass index (BMI) risk factor, even a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2013-06, Vol.71 (Suppl 3), p.699
Hauptverfasser: Del Pino, J., Pedrero, R., Lopez-Gonzalez, R., Montilla-Morales, C., Gomez-Castro, S., Sanchez-Gonzalez, M.D., Hidalgo-Calleja, C., García-Talavera, P.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background The increase of pro-inflammatory cytoquines plays a relevant role in the loss of bone density which is associated to the Rheumatoid Arthritis (RA). The glucocorticosteroids (GC) are in the base of the treatment and have been described as a losing body mass index (BMI) risk factor, even a small continuing dosage, based in that suggestion it is consider the use of GC in RA patients a combination of risk factor of fracture, which it is reflected in the absolute risk calculator as the FRAX index. There are studies which have compared the use of GC in patients related with healthy control, but there are not studies which related the effect at the BMI of the GC prescription in RA patients. Objectives To estimate the BMI variation in RA patients treated with GC Methods Longitudinal study of 69 women with RA, during 5 years. Socio-demographic, clinical and BMI characteristics were recorded, which was measure with dual-emission X-ray absorptiometry technique in two levels total lumbar spine and femoral neck. Descriptive analyses were performed, and was described the predictors of decreased of the BMI in patients treated with GC and/or bisfosfonates (BPS) drugs, a value p
ISSN:0003-4967
1468-2060
DOI:10.1136/annrheumdis-2012-eular.1062